DK1685243T3 - Immortaliserede fuglecellelinjer til virusproduktion - Google Patents

Immortaliserede fuglecellelinjer til virusproduktion

Info

Publication number
DK1685243T3
DK1685243T3 DK04798154T DK04798154T DK1685243T3 DK 1685243 T3 DK1685243 T3 DK 1685243T3 DK 04798154 T DK04798154 T DK 04798154T DK 04798154 T DK04798154 T DK 04798154T DK 1685243 T3 DK1685243 T3 DK 1685243T3
Authority
DK
Denmark
Prior art keywords
cell lines
immortalized
virus production
bird cell
production
Prior art date
Application number
DK04798154T
Other languages
English (en)
Inventor
Volker Sandig
Ingo Jordan
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34400514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1685243(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiogen Ag filed Critical Probiogen Ag
Application granted granted Critical
Publication of DK1685243T3 publication Critical patent/DK1685243T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251—Methods of production or purification of viral material
    • C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04798154T 2003-11-03 2004-11-03 Immortaliserede fuglecellelinjer til virusproduktion DK1685243T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025158A EP1528101A1 (en) 2003-11-03 2003-11-03 Immortalized avian cell lines for virus production
PCT/EP2004/052789 WO2005042728A2 (en) 2003-11-03 2004-11-03 Immortalized avian cell lines for virus production

Publications (1)

Publication Number Publication Date
DK1685243T3 true DK1685243T3 (da) 2008-10-20

Family

ID=34400514

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04798154T DK1685243T3 (da) 2003-11-03 2004-11-03 Immortaliserede fuglecellelinjer til virusproduktion
DK08101999.4T DK1939281T4 (da) 2003-11-03 2004-11-03 Immortaliserede andecellelinjer til virusproduktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08101999.4T DK1939281T4 (da) 2003-11-03 2004-11-03 Immortaliserede andecellelinjer til virusproduktion

Country Status (18)

Country Link
US (2) US8940534B2 (da)
EP (4) EP1528101A1 (da)
JP (1) JP4658953B2 (da)
KR (1) KR101027755B1 (da)
CN (1) CN1934243B (da)
AT (2) ATE398672T1 (da)
AU (1) AU2004285089B2 (da)
BR (1) BRPI0415622B8 (da)
CA (1) CA2544462C (da)
CY (1) CY1110272T1 (da)
DE (2) DE602004025996D1 (da)
DK (2) DK1685243T3 (da)
ES (1) ES2309578T3 (da)
PL (1) PL1685243T3 (da)
PT (1) PT1685243E (da)
RU (1) RU2359999C2 (da)
SI (1) SI1685243T1 (da)
WO (1) WO2005042728A2 (da)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1646715E (pt) * 2003-07-22 2010-08-09 Vivalis Produção de poxvírus com linhagem das células aviarias aderentes ou não aderentes
PT1789084E (pt) 2004-09-09 2011-02-22 Novartis Vaccines & Diagnostic Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US20090220541A1 (en) 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
EP1783210A1 (en) 2005-11-08 2007-05-09 ProBioGen AG Productivity augmenting protein factors, novel cell lines and uses thereof
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348B1 (en) 2006-09-11 2025-03-26 Seqirus UK Limited Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
US8361788B2 (en) * 2007-07-03 2013-01-29 Transgene S.A. Immortalized avian cell lines comprising E1A nucleic acid sequences
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
KR20140096162A (ko) * 2008-02-25 2014-08-04 백스터 인터내셔널 인코포레이티드 연속 세포주 제조 방법
US8679839B2 (en) * 2008-03-04 2014-03-25 Probiogen Ag Cell line from rousettus as host cell for pathogen amplification
EP2098590A1 (en) 2008-03-04 2009-09-09 ProBioGen AG Cell line from Rousettus as host cell for pathogen amplification
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
WO2009156155A1 (en) * 2008-06-25 2009-12-30 Probiogen Ag Cell line for propagation of highly attenuated alphaviruses
EP2199385A1 (en) 2008-12-16 2010-06-23 ProBioGen AG Specific and persistent activation of heat shock response in cell lines using a viral factor
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
CA2750055A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
JP5688373B2 (ja) * 2009-09-30 2015-03-25 国立大学法人帯広畜産大学 α−ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
JP2013521771A (ja) 2010-03-08 2013-06-13 ノバルティス アーゲー 細胞内病原体について試験する方法
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスｂ１９のウイルス様粒子を生成するための方法
US20130203151A1 (en) 2010-04-26 2013-08-08 Scott Balsitis Production of alphavirus replicon particles in packaging cells
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
CA2796213A1 (en) 2010-05-06 2011-11-10 Novartis Ag Organic peroxide compounds for microorganism inactivation
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
CN102939104A (zh) 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
KR102113512B1 (ko) 2010-06-01 2020-05-22 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EP2635682B1 (en) * 2010-11-02 2017-07-19 Helmholtz-Zentrum für Infektionsforschung GmbH Methods and vectors for cell immortalisation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
EP4144368B1 (en) 2011-01-26 2025-02-26 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
US20140271829A1 (en) 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
EP2766385A2 (en) 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
MX2015006377A (es) 2012-11-20 2015-07-21 Glaxosmithkline Biolog Sa Trimeros prefusion de f de vsr.
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
WO2014108515A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
CA2920934C (en) 2013-08-30 2022-12-06 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
WO2015153708A1 (en) * 2014-04-02 2015-10-08 Synageva Biopharma Corp. Producing therapeutic proteins
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
JP6546659B2 (ja) * 2014-12-04 2019-07-17 インターベット インターナショナル ベー． フェー． 不死化ニワトリ胚線維芽細胞
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
BE1023903B1 (fr) 2014-12-16 2017-09-08 Glaxosmithkline Biologicals Sa Nouveau procédé
ES2784264T3 (es) 2014-12-17 2020-09-23 Fundacion Para La Investig Medica Aplicada Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson y otras afecciones
JP6865167B2 (ja) 2014-12-17 2021-04-28 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
IL302693B2 (en) * 2016-07-11 2025-10-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Methods and systems for growing cells in culture
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN107012122A (zh) * 2016-12-12 2017-08-04 江苏省农业科学院 一种永生化鸡胚胎肝细胞系及其制备方法和用途
EP3562946B1 (en) 2016-12-28 2021-11-24 Transgene SA Oncolytic viruses and therapeutic molecules
BR112019019813A2 (pt) 2017-03-30 2020-04-22 The University Of Queensland moléculas quiméricas e usos das mesmas
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
US20210180084A1 (en) 2018-05-14 2021-06-17 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CA3106286A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN110396496B (zh) * 2018-09-30 2023-06-20 湖北省农业科学院畜牧兽医研究所 一种鸭小肠上皮细胞的培养方法及应用
CA3116098A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
JP2022512930A (ja) 2018-11-07 2022-02-07 ヴィヴェ テラピューティクス 進行性家族性肝内胆汁鬱滞タイプ２（ｐｆｉｃ２）の治療のためのコドン最適化ａｂｃｂ１１導入遺伝子
CN109321516A (zh) * 2018-11-07 2019-02-12 贵州大学 一种鸭原代肝细胞分离及培养方法
EP3880809A4 (en) 2018-11-16 2023-01-11 Encoded Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF WILSON'S DISEASE
EP3884039A1 (en) 2018-11-23 2021-09-29 Valneva SE Food products comprising avian stem cells
US12478571B2 (en) 2018-12-17 2025-11-25 Pontis Biologics, Inc. Enzyme based compositions and methods for removing dental calculi
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
EP3686276A1 (en) * 2019-01-28 2020-07-29 Freie Universität Berlin Production of viruses in continuously growing epithelial cell lines derived from chicken gut
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
CA3145446A1 (en) 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada Cpla2e inducing agents and uses thereof
CN114206909A (zh) 2019-07-21 2022-03-18 葛兰素史克生物有限公司 治疗性病毒疫苗
US12419949B2 (en) 2019-07-24 2025-09-23 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
JP2021136899A (ja) * 2020-03-04 2021-09-16 花王株式会社 ウイルス増殖方法及びウイルス増殖促進剤の探索方法
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
TW202214864A (zh) 2020-08-06 2022-04-16 應用醫學研究基金會 用於藉基因療法治療諸如阿茲海默症之Ｔａｕ蛋白病變的病毒顆粒
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
CN116390935A (zh) 2020-10-09 2023-07-04 Ucb生物制药有限责任公司 核酸构建体、病毒载体和病毒颗粒
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
AU2022206415A1 (en) 2021-01-10 2023-08-17 Supermeat The Essence Of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
IL316712B2 (en) 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
EP4419650A1 (en) 2021-10-18 2024-08-28 Supermeat the Essence of Meat Ltd. Methods for preparing a food ingredient and compositions produced thereby
JP2024543001A (ja) 2021-10-28 2024-11-19 ユーシービー バイオファルマ エスアールエル 核酸構築物、ウイルスベクターおよびウイルス粒子
CN114350601B (zh) * 2021-12-21 2022-12-27 广东省华晟生物技术有限公司 樱桃谷鸭成纤维细胞系及其构建方法与应用
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins
CN114908053A (zh) * 2022-04-24 2022-08-16 上海交通大学 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
CN116496992B (zh) * 2023-04-24 2023-12-01 江苏省家禽科学研究所 一种鸡胚成肌永生化细胞及其构建方法和应用
WO2025120141A1 (en) * 2023-12-08 2025-06-12 Bavarian Nordic A/S Downregulation of yield-reducing transgenes expressed by poxvirus
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
KR970010968A (ko) 1995-08-24 1997-03-27 윤원영 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
FR2749022B1 (fr) * 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
FR2767335B1 (fr) 1997-08-14 2001-09-28 Ct Nat D Etudes Veterinaires E Adenovirus aviaire celo recombinant comme vecteur vaccinant
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
CN1139655C (zh) * 2001-08-23 2004-02-25 北京大学人民医院 一种人卵巢癌永生化细胞株及其建立方法
DE60336653D1 (de) 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
PT1646715E (pt) 2003-07-22 2010-08-09 Vivalis Produção de poxvírus com linhagem das células aviarias aderentes ou não aderentes

Also Published As

Publication number Publication date
CN1934243B (zh) 2011-07-06
EP1685243A2 (en) 2006-08-02
BRPI0415622B8 (pt) 2021-05-25
DE602004014526D1 (de) 2008-07-31
EP1685243B1 (en) 2008-06-18
WO2005042728A2 (en) 2005-05-12
JP2007510409A (ja) 2007-04-26
KR20060123758A (ko) 2006-12-04
DK1939281T4 (da) 2014-08-25
KR101027755B1 (ko) 2011-04-07
WO2005042728A3 (en) 2005-07-07
EP1528101A1 (en) 2005-05-04
US20080227146A1 (en) 2008-09-18
CA2544462A1 (en) 2005-05-12
ATE398672T1 (de) 2008-07-15
JP4658953B2 (ja) 2011-03-23
RU2359999C2 (ru) 2009-06-27
RU2006119447A (ru) 2007-12-20
US20120288916A1 (en) 2012-11-15
CN1934243A (zh) 2007-03-21
AU2004285089A1 (en) 2005-05-12
PL1685243T3 (pl) 2008-12-31
DE602004025996D1 (de) 2010-04-22
BRPI0415622B1 (pt) 2021-01-26
BRPI0415622A (pt) 2006-12-12
AU2004285089B2 (en) 2009-07-02
CA2544462C (en) 2011-10-25
US8940534B2 (en) 2015-01-27
EP2192173A1 (en) 2010-06-02
EP1939281B1 (en) 2010-03-10
DK1939281T3 (da) 2010-06-14
EP1939281B2 (en) 2014-06-04
ES2309578T3 (es) 2008-12-16
SI1685243T1 (sl) 2008-12-31
PT1685243E (pt) 2008-09-24
EP1939281A1 (en) 2008-07-02
ATE460473T1 (de) 2010-03-15
CY1110272T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
ATE398672T1 (de) Immortalisierte vogelzellinien zur virusproduktion
DE50214416D1 (de) Vermehrung von viren in zellkultur
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
MX2018001040A (es) Moleculas de acido nucleico artificiales.
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
EP4659816A3 (en) MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY
CY1119106T1 (el) Αντισωματα εναντι masp-2
EA200970996A1 (ru) Стволовые клеточные линии, полученные из эмбрионов утки, для производства вирусных вакцин
EA201001045A1 (ru) Модифицированный вирус гриппа
MX2016008551A (es) Moleculas artificiales de acido nucleico.
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
CY1121438T1 (el) Μεθοδοι για την παρασκευη υδροπηκτων χρησιμοποιωντας ενζυμα λιπασης
EP1723238A4 (en) MODIFIED ONCOLYTIC VIRUSES
ATE507242T1 (de) Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
IL292053A (en) Compositions, methods and kits for biological sample and rna stabilization
EP4494651A3 (en) Modified viruses
EP1989316A4 (en) METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
DK1537204T3 (da) Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a